Loading news...
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. This marks the third orphan designation for LP-284, following previous orphan designations in Mantle Cell Lymphoma (MCL.
DALLAS--(BUSINESS WIRE)--A.I. center of excellence - Lantern Pharma.
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.
Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - President, CEO & Director Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Reggie Ewesuedo Conference Call Participants Igor Astsaturov Presentation Panna Sharma President, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar.
Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Good morning, and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded [Operator Instructions].
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025.
DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184.
AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
DALLAS--(BUSINESS WIRE)--Q2 2025 Financial Results & Business Updates.
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, to.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses one of pharmaceutical development's most persistent challenges—that only 2-6% of small-molecule drugs can successful.
DALLAS--(BUSINESS WIRE)--Harmonic Trial - Japan Cohort Completion.
DALLAS--(BUSINESS WIRE)--Dr. Lee Schalop Joins Lantern Pharma BOD.